• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BDA
Click for more information
1.06% 46.5¢

BOD AUSTRALIA LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BDA Clinical Trial demonstrates Bod's CBD Wafer superiorityPRICE SENSITIVE26/03/19
BDA Bod progresses European expansion following LOI with TilmanPRICE SENSITIVE11/03/19
BDA Ceasing to be a substantial holder06/03/19
BDA Bod expands medicinal cannabis product suitePRICE SENSITIVE01/03/19
BDA Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
BDA Bod continues to attract industry leading managementPRICE SENSITIVE19/02/19
BDA Becoming a substantial holder12/02/19
BDA Becoming a substantial holder11/02/19
BDA Asia and Australian Roadshow PresentationPRICE SENSITIVE06/02/19
BDA Resignation of M Perrett as Director and Appendix 3Z22/01/19
BDA Appendix 3Y - George Livery and Jo Patterson17/01/19
BDA Quarterly Report and Appendix 4CPRICE SENSITIVE16/01/19
BDA Change of Director's Interest Notice17/12/18
BDA Ceasing to be a substantial holder03/12/18
BDA Appendix 3Y - Change of Director's Interest Notices28/11/18
BDA Section 708A Cleansing Notice28/11/18
BDA Appendix 3B28/11/18
BDA Bod Granted Licence to Export Medicinal CannabisPRICE SENSITIVE20/11/18
BDA Results of Annual General Meeting19/11/18
BDA Audio interview with Bod Australia CEO Jo Patterson13/11/18
BDA Becoming a substantial holder12/11/18
BDA Bod has aligned with Chemist Warehouse GroupPRICE SENSITIVE09/11/18
BDA Appendix 3B08/11/18
BDA Quarterly Report and Appendix 4CPRICE SENSITIVE31/10/18
BDA Bod secures first medicinal cannabis prescriptionPRICE SENSITIVE25/10/18
BDA Annual Report to shareholders19/10/18
BDA Appendix 4G and Corporate Governance Statement19/10/18
BDA Notice of Annual General Meeting/Proxy Form18/10/18
BDA Investor Presentation18/10/18
BDA Bod Achieves Word First in Phase 1 Clinical TrialPRICE SENSITIVE16/10/18
BDA Becoming a substantial holder15/10/18
BDA S708A Cleansing Notice09/10/18
BDA Restricted securities to be released from escrow08/10/18
BDA Appendix 3B08/10/18
BDA Becoming a substantial holder04/10/18
BDA Bod Completes $6.4m Strategic PlacementPRICE SENSITIVE28/09/18
BDA Trading HaltPRICE SENSITIVE26/09/18
BDA Bod and Lambert Initiative enter research collaborationPRICE SENSITIVE25/09/18
BDA Mamacare distribution agreement with Priceline PharmacyPRICE SENSITIVE19/09/18
BDA Initial Directors Interest Notice - Mr Stephen Thompson06/09/18
BDA Initial Directors Interest Notice - Mr George Livery06/09/18
BDA Company Secretary Appointment/Resignation05/09/18
BDA Appendix 4E and Audited Financial StatementsPRICE SENSITIVE31/08/18
BDA Appointment of Mr Stephen Thompson as Executive Director21/08/18
BDA Appendix 3B07/08/18
BDA Quarterly Report and Appendix 4CPRICE SENSITIVE31/07/18
BDA Results of General Meeting24/07/18 download Created with Sketch. 78.67KB
BDA Bod commences Phase I Clinical trialPRICE SENSITIVE24/07/18 download Created with Sketch. 63.87KB
BDA Notice of Extraordinary General Meeting & Proxy Form22/06/18 download Created with Sketch. 290.62KB
BDA Bod signs agreement with SymbionPRICE SENSITIVE05/06/18 download Created with Sketch. 67.66KB
BDA Ceasing to be a substantial holder04/06/18 download Created with Sketch. 127.41KB
BDA Becoming a substantial holder04/06/18 download Created with Sketch. 138.98KB
BDA Appointment of Executive Chairman30/05/18 download Created with Sketch. 159.75KB
BDA Appendix 3B & s708A Notice24/05/18 download Created with Sketch. 490.66KB
BDA Trial ready Cannabis Sublingual Wafer Formulation completePRICE SENSITIVE11/05/18
BDA Change of Auditor01/05/18
BDA Cannabis Phase I Clinical Trial - Ethics Approval ReceivedPRICE SENSITIVE01/05/18
BDA Quarterly Report and Appendix 4CPRICE SENSITIVE30/04/18
BDA Bod completes first order of medicinal cannabis oilPRICE SENSITIVE12/04/18
BDA Symbion to distribute Bod portfolio of natural medicinesPRICE SENSITIVE09/04/18
BDA API to stock full Bod portfolio of natural medicinesPRICE SENSITIVE05/04/18
BDA Bod Australia investor evening27/03/18
BDA Bod completes import of first cannabis productsPRICE SENSITIVE26/03/18
BDA Investor Presentation02/03/18
BDA Bod delivers strong first half performance27/02/18
BDA Half Yearly Report and AccountsPRICE SENSITIVE27/02/18
BDA Bods exclusive partner iX Biopharma secures China patentPRICE SENSITIVE26/02/18
BDA Bod to commence importing medicinal cannabis oilPRICE SENSITIVE23/02/18
BDA Agreement with In2pharma & expansion of Health Product rangePRICE SENSITIVE14/02/18
BDA Bod commences import of cannabis productsPRICE SENSITIVE05/02/18
BDA Quarterly Report and Appendix 4CPRICE SENSITIVE24/01/18
BDA Agreement to develop Hemp Manuka Honey Product LinePRICE SENSITIVE18/01/18
BDA Update on Fast Track of Phase I Clinical Trials11/01/18
BDA Agreement with iX Biopharma LtdPRICE SENSITIVE04/01/18
BDA S708A Cleansing Notice28/12/17
BDA Appendix 3B28/12/17
BDA S708A Cleansing Notice27/12/17
BDA Appendix 3B27/12/17
BDA Becoming a substantial holder22/12/17
BDA Bod Completes $3.2m Strategic PlacementPRICE SENSITIVE18/12/17
BDA Trading HaltPRICE SENSITIVE14/12/17
BDA Strong growth and expansion of footprint into ChinaPRICE SENSITIVE13/12/17
BDA Reinstatement to Official QuotationPRICE SENSITIVE08/12/17
BDA Bod Australia reinstated to Official QuotationPRICE SENSITIVE08/12/17
BDA Medicinal Cannabis Import Licence GrantedPRICE SENSITIVE05/12/17
BDA Suspension from Official QuotationPRICE SENSITIVE05/12/17
BDA Trading HaltPRICE SENSITIVE01/12/17
BDA Investor Presentation23/11/17
BDA Change of Director's Interest Notice - Mickey Perret21/11/17
BDA Appendix 3B - Issue of Unlisted Options17/11/17
BDA Results of Annual General Meeting15/11/17
BDA Bod begins formulating cannabis-based cosmetics productsPRICE SENSITIVE10/11/17
BDA Pregnancy supplement distribution deal securedPRICE SENSITIVE08/11/17
BDA Restricted Securities to be released from Escrow27/10/17
BDA Quarterly Report & Appendix 4CPRICE SENSITIVE27/10/17
BDA Bod formalises Agreement with LinneaPRICE SENSITIVE23/10/17
BDA Annual Report with Chairman & CEO's address to Shareholders16/10/17
BDA Notice of Annual General Meeting & Proxy Form16/10/17
BDA Restricted Securities to be released from escrow05/10/17
BDA Research supports approach to medicinal cannabis extractsPRICE SENSITIVE26/09/17
BDA Clinical Trial demonstrates Bod's CBD Wafer superiority
26/03/19PRICE SENSITIVE
BDA Bod progresses European expansion following LOI with Tilman
11/03/19PRICE SENSITIVE
BDA Ceasing to be a substantial holder
06/03/19
BDA Bod expands medicinal cannabis product suite
01/03/19PRICE SENSITIVE
BDA Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
BDA Bod continues to attract industry leading management
19/02/19PRICE SENSITIVE
BDA Becoming a substantial holder
12/02/19
BDA Becoming a substantial holder
11/02/19
BDA Asia and Australian Roadshow Presentation
06/02/19PRICE SENSITIVE
BDA Resignation of M Perrett as Director and Appendix 3Z
22/01/19
BDA Appendix 3Y - George Livery and Jo Patterson
17/01/19
BDA Quarterly Report and Appendix 4C
16/01/19PRICE SENSITIVE
BDA Change of Director's Interest Notice
17/12/18
BDA Ceasing to be a substantial holder
03/12/18
BDA Appendix 3Y - Change of Director's Interest Notices
28/11/18
BDA Section 708A Cleansing Notice
28/11/18
BDA Appendix 3B
28/11/18
BDA Bod Granted Licence to Export Medicinal Cannabis
20/11/18PRICE SENSITIVE
BDA Results of Annual General Meeting
19/11/18
BDA Audio interview with Bod Australia CEO Jo Patterson
13/11/18
BDA Becoming a substantial holder
12/11/18
BDA Bod has aligned with Chemist Warehouse Group
09/11/18PRICE SENSITIVE
BDA Appendix 3B
08/11/18
BDA Quarterly Report and Appendix 4C
31/10/18PRICE SENSITIVE
BDA Bod secures first medicinal cannabis prescription
25/10/18PRICE SENSITIVE
BDA Annual Report to shareholders
19/10/18
BDA Appendix 4G and Corporate Governance Statement
19/10/18
BDA Notice of Annual General Meeting/Proxy Form
18/10/18
BDA Investor Presentation
18/10/18
BDA Bod Achieves Word First in Phase 1 Clinical Trial
16/10/18PRICE SENSITIVE
BDA Becoming a substantial holder
15/10/18
BDA S708A Cleansing Notice
09/10/18
BDA Restricted securities to be released from escrow
08/10/18
BDA Appendix 3B
08/10/18
BDA Becoming a substantial holder
04/10/18
BDA Bod Completes $6.4m Strategic Placement
28/09/18PRICE SENSITIVE
BDA Trading Halt
26/09/18PRICE SENSITIVE
BDA Bod and Lambert Initiative enter research collaboration
25/09/18PRICE SENSITIVE
BDA Mamacare distribution agreement with Priceline Pharmacy
19/09/18PRICE SENSITIVE
BDA Initial Directors Interest Notice - Mr Stephen Thompson
06/09/18
BDA Initial Directors Interest Notice - Mr George Livery
06/09/18
BDA Company Secretary Appointment/Resignation
05/09/18
BDA Appendix 4E and Audited Financial Statements
31/08/18PRICE SENSITIVE
BDA Appointment of Mr Stephen Thompson as Executive Director
21/08/18
BDA Appendix 3B
07/08/18
BDA Quarterly Report and Appendix 4C
31/07/18PRICE SENSITIVE
BDA Results of General Meeting
24/07/18 download Created with Sketch. 78.67KB
BDA Bod commences Phase I Clinical trial
24/07/18PRICE SENSITIVE download Created with Sketch. 63.87KB
BDA Notice of Extraordinary General Meeting & Proxy Form
22/06/18 download Created with Sketch. 290.62KB
BDA Bod signs agreement with Symbion
05/06/18PRICE SENSITIVE download Created with Sketch. 67.66KB
BDA Ceasing to be a substantial holder
04/06/18 download Created with Sketch. 127.41KB
BDA Becoming a substantial holder
04/06/18 download Created with Sketch. 138.98KB
BDA Appointment of Executive Chairman
30/05/18 download Created with Sketch. 159.75KB
BDA Appendix 3B & s708A Notice
24/05/18 download Created with Sketch. 490.66KB
BDA Trial ready Cannabis Sublingual Wafer Formulation complete
11/05/18PRICE SENSITIVE
BDA Change of Auditor
01/05/18
BDA Cannabis Phase I Clinical Trial - Ethics Approval Received
01/05/18PRICE SENSITIVE
BDA Quarterly Report and Appendix 4C
30/04/18PRICE SENSITIVE
BDA Bod completes first order of medicinal cannabis oil
12/04/18PRICE SENSITIVE
BDA Symbion to distribute Bod portfolio of natural medicines
09/04/18PRICE SENSITIVE
BDA API to stock full Bod portfolio of natural medicines
05/04/18PRICE SENSITIVE
BDA Bod Australia investor evening
27/03/18
BDA Bod completes import of first cannabis products
26/03/18PRICE SENSITIVE
BDA Investor Presentation
02/03/18
BDA Bod delivers strong first half performance
27/02/18
BDA Half Yearly Report and Accounts
27/02/18PRICE SENSITIVE
BDA Bods exclusive partner iX Biopharma secures China patent
26/02/18PRICE SENSITIVE
BDA Bod to commence importing medicinal cannabis oil
23/02/18PRICE SENSITIVE
BDA Agreement with In2pharma & expansion of Health Product range
14/02/18PRICE SENSITIVE
BDA Bod commences import of cannabis products
05/02/18PRICE SENSITIVE
BDA Quarterly Report and Appendix 4C
24/01/18PRICE SENSITIVE
BDA Agreement to develop Hemp Manuka Honey Product Line
18/01/18PRICE SENSITIVE
BDA Update on Fast Track of Phase I Clinical Trials
11/01/18
BDA Agreement with iX Biopharma Ltd
04/01/18PRICE SENSITIVE
BDA S708A Cleansing Notice
28/12/17
BDA Appendix 3B
28/12/17
BDA S708A Cleansing Notice
27/12/17
BDA Appendix 3B
27/12/17
BDA Becoming a substantial holder
22/12/17
BDA Bod Completes $3.2m Strategic Placement
18/12/17PRICE SENSITIVE
BDA Trading Halt
14/12/17PRICE SENSITIVE
BDA Strong growth and expansion of footprint into China
13/12/17PRICE SENSITIVE
BDA Reinstatement to Official Quotation
08/12/17PRICE SENSITIVE
BDA Bod Australia reinstated to Official Quotation
08/12/17PRICE SENSITIVE
BDA Medicinal Cannabis Import Licence Granted
05/12/17PRICE SENSITIVE
BDA Suspension from Official Quotation
05/12/17PRICE SENSITIVE
BDA Trading Halt
01/12/17PRICE SENSITIVE
BDA Investor Presentation
23/11/17
BDA Change of Director's Interest Notice - Mickey Perret
21/11/17
BDA Appendix 3B - Issue of Unlisted Options
17/11/17
BDA Results of Annual General Meeting
15/11/17
BDA Bod begins formulating cannabis-based cosmetics products
10/11/17PRICE SENSITIVE
BDA Pregnancy supplement distribution deal secured
08/11/17PRICE SENSITIVE
BDA Restricted Securities to be released from Escrow
27/10/17
BDA Quarterly Report & Appendix 4C
27/10/17PRICE SENSITIVE
BDA Bod formalises Agreement with Linnea
23/10/17PRICE SENSITIVE
BDA Annual Report with Chairman & CEO's address to Shareholders
16/10/17
BDA Notice of Annual General Meeting & Proxy Form
16/10/17
BDA Restricted Securities to be released from escrow
05/10/17
BDA Research supports approach to medicinal cannabis extracts
26/09/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke Southern Cross Gold Ltd has found 5.5 metres at 25.4 g/t, with drilling highlighting the presence of multiple zones of mineralisation
Chimeric clocks $4.17M R&D tax rebate from Canberra Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17M tax rebate from Canberra for R&D activities.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.